Acute exacerbation of rheumatoid arthritis–associated interstitial lung disease: clinical features and prognosis
Abstract Objectives RA-associated interstitial lung disease (RA-ILD) is commonly associated with acute exacerbations (ILD-AE). This study examined the clinical characteristics and risk factors of ILD-AE and mortality of RA-ILD. Methods We retrospectively collected data on 165 RA-ILD patients who vis...
Saved in:
Published in | Rheumatology (Oxford, England) Vol. 60; no. 5; pp. 2348 - 2354 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
Oxford University Press
14.05.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Objectives
RA-associated interstitial lung disease (RA-ILD) is commonly associated with acute exacerbations (ILD-AE). This study examined the clinical characteristics and risk factors of ILD-AE and mortality of RA-ILD.
Methods
We retrospectively collected data on 165 RA-ILD patients who visited or were admitted to our hospital between January 2007 and December 2019. We compared the clinical characteristics of patients who did and did not develop ILD-AE and identified variables significantly associated with ILD-AE. We also compared the admission characteristics of those who survived and those who died after admission for ILD-AE. ILD-AE was defined using previously proposed criteria, modified slightly for application to RA-ILD.
Results
The mean patient age was 73.6 years (s.d. 9.7) and 97 (71.9%) patients were female. Thirty (22.2%) patients developed ILD-AE, 13 (43.3%) of whom died. In univariate analyses, neither the usual interstitial pneumonia (UIP) pattern nor MTX was associated with ILD-AE. In multivariate analyses, the UIP pattern was significantly associated with ILD-AE [odds ratio (OR) 2.55 (95% CI 1.05, 6.20), P = 0.038]. In the Cox proportional hazards model, the UIP pattern [hazard ratio (HR) 4.67 (95% CI 1.02, 21.45), P = 0.048] was significantly associated with death, while MTX use [HR 0.16 (95% CI 0.04, 0.72), P = 0.016] was significantly associated with survival.
Conclusion
Our data suggest that the UIP pattern is related to ILD-AE. Furthermore, both the UIP pattern and non-use of MTX might be related to death from ILD-AE in RA-ILD. |
---|---|
AbstractList | RA-associated interstitial lung disease (RA-ILD) is commonly associated with acute exacerbations (ILD-AE). This study examined the clinical characteristics and risk factors of ILD-AE and mortality of RA-ILD.
We retrospectively collected data on 165 RA-ILD patients who visited or were admitted to our hospital between January 2007 and December 2019. We compared the clinical characteristics of patients who did and did not develop ILD-AE and identified variables significantly associated with ILD-AE. We also compared the admission characteristics of those who survived and those who died after admission for ILD-AE. ILD-AE was defined using previously proposed criteria, modified slightly for application to RA-ILD.
The mean patient age was 73.6 years (s.d. 9.7) and 97 (71.9%) patients were female. Thirty (22.2%) patients developed ILD-AE, 13 (43.3%) of whom died. In univariate analyses, neither the usual interstitial pneumonia (UIP) pattern nor MTX was associated with ILD-AE. In multivariate analyses, the UIP pattern was significantly associated with ILD-AE [odds ratio (OR) 2.55 (95% CI 1.05, 6.20), P = 0.038]. In the Cox proportional hazards model, the UIP pattern [hazard ratio (HR) 4.67 (95% CI 1.02, 21.45), P = 0.048] was significantly associated with death, while MTX use [HR 0.16 (95% CI 0.04, 0.72), P = 0.016] was significantly associated with survival.
Our data suggest that the UIP pattern is related to ILD-AE. Furthermore, both the UIP pattern and non-use of MTX might be related to death from ILD-AE in RA-ILD. Abstract Objectives RA-associated interstitial lung disease (RA-ILD) is commonly associated with acute exacerbations (ILD-AE). This study examined the clinical characteristics and risk factors of ILD-AE and mortality of RA-ILD. Methods We retrospectively collected data on 165 RA-ILD patients who visited or were admitted to our hospital between January 2007 and December 2019. We compared the clinical characteristics of patients who did and did not develop ILD-AE and identified variables significantly associated with ILD-AE. We also compared the admission characteristics of those who survived and those who died after admission for ILD-AE. ILD-AE was defined using previously proposed criteria, modified slightly for application to RA-ILD. Results The mean patient age was 73.6 years (s.d. 9.7) and 97 (71.9%) patients were female. Thirty (22.2%) patients developed ILD-AE, 13 (43.3%) of whom died. In univariate analyses, neither the usual interstitial pneumonia (UIP) pattern nor MTX was associated with ILD-AE. In multivariate analyses, the UIP pattern was significantly associated with ILD-AE [odds ratio (OR) 2.55 (95% CI 1.05, 6.20), P = 0.038]. In the Cox proportional hazards model, the UIP pattern [hazard ratio (HR) 4.67 (95% CI 1.02, 21.45), P = 0.048] was significantly associated with death, while MTX use [HR 0.16 (95% CI 0.04, 0.72), P = 0.016] was significantly associated with survival. Conclusion Our data suggest that the UIP pattern is related to ILD-AE. Furthermore, both the UIP pattern and non-use of MTX might be related to death from ILD-AE in RA-ILD. RA-associated interstitial lung disease (RA-ILD) is commonly associated with acute exacerbations (ILD-AE). This study examined the clinical characteristics and risk factors of ILD-AE and mortality of RA-ILD.OBJECTIVESRA-associated interstitial lung disease (RA-ILD) is commonly associated with acute exacerbations (ILD-AE). This study examined the clinical characteristics and risk factors of ILD-AE and mortality of RA-ILD.We retrospectively collected data on 165 RA-ILD patients who visited or were admitted to our hospital between January 2007 and December 2019. We compared the clinical characteristics of patients who did and did not develop ILD-AE and identified variables significantly associated with ILD-AE. We also compared the admission characteristics of those who survived and those who died after admission for ILD-AE. ILD-AE was defined using previously proposed criteria, modified slightly for application to RA-ILD.METHODSWe retrospectively collected data on 165 RA-ILD patients who visited or were admitted to our hospital between January 2007 and December 2019. We compared the clinical characteristics of patients who did and did not develop ILD-AE and identified variables significantly associated with ILD-AE. We also compared the admission characteristics of those who survived and those who died after admission for ILD-AE. ILD-AE was defined using previously proposed criteria, modified slightly for application to RA-ILD.The mean patient age was 73.6 years (s.d. 9.7) and 97 (71.9%) patients were female. Thirty (22.2%) patients developed ILD-AE, 13 (43.3%) of whom died. In univariate analyses, neither the usual interstitial pneumonia (UIP) pattern nor MTX was associated with ILD-AE. In multivariate analyses, the UIP pattern was significantly associated with ILD-AE [odds ratio (OR) 2.55 (95% CI 1.05, 6.20), P = 0.038]. In the Cox proportional hazards model, the UIP pattern [hazard ratio (HR) 4.67 (95% CI 1.02, 21.45), P = 0.048] was significantly associated with death, while MTX use [HR 0.16 (95% CI 0.04, 0.72), P = 0.016] was significantly associated with survival.RESULTSThe mean patient age was 73.6 years (s.d. 9.7) and 97 (71.9%) patients were female. Thirty (22.2%) patients developed ILD-AE, 13 (43.3%) of whom died. In univariate analyses, neither the usual interstitial pneumonia (UIP) pattern nor MTX was associated with ILD-AE. In multivariate analyses, the UIP pattern was significantly associated with ILD-AE [odds ratio (OR) 2.55 (95% CI 1.05, 6.20), P = 0.038]. In the Cox proportional hazards model, the UIP pattern [hazard ratio (HR) 4.67 (95% CI 1.02, 21.45), P = 0.048] was significantly associated with death, while MTX use [HR 0.16 (95% CI 0.04, 0.72), P = 0.016] was significantly associated with survival.Our data suggest that the UIP pattern is related to ILD-AE. Furthermore, both the UIP pattern and non-use of MTX might be related to death from ILD-AE in RA-ILD.CONCLUSIONOur data suggest that the UIP pattern is related to ILD-AE. Furthermore, both the UIP pattern and non-use of MTX might be related to death from ILD-AE in RA-ILD. |
Author | Izuka, Shinji Takahashi, Yuko Kaneko, Hiroshi Yamashita, Hiroyuki Iba, Arisa |
Author_xml | – sequence: 1 givenname: Shinji orcidid: 0000-0002-9724-4911 surname: Izuka fullname: Izuka, Shinji organization: Division of Rheumatic Diseases, National Center for Global Health and Medicine, Tokyo, Japan – sequence: 2 givenname: Hiroyuki orcidid: 0000-0002-0022-1941 surname: Yamashita fullname: Yamashita, Hiroyuki email: hiroyuki_yjp2005@yahoo.co.jp organization: Division of Rheumatic Diseases, National Center for Global Health and Medicine, Tokyo, Japan – sequence: 3 givenname: Arisa surname: Iba fullname: Iba, Arisa organization: Department of Public Health, Graduate School of Medicine, University of Tokyo, Tokyo, Japan – sequence: 4 givenname: Yuko surname: Takahashi fullname: Takahashi, Yuko organization: Division of Rheumatic Diseases, National Center for Global Health and Medicine, Tokyo, Japan – sequence: 5 givenname: Hiroshi surname: Kaneko fullname: Kaneko, Hiroshi organization: Division of Rheumatic Diseases, National Center for Global Health and Medicine, Tokyo, Japan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33241299$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkc9OGzEQxq0KVP6-QYV85JLG9jq7Xm5RBG2lSL1wX816Z4NhYwePV4Ib78Ab9klqmgRVvZTTjL75fTPSfCfswAePjH2R4qsUdTGNdziuIYUhrJ6nDwhQCvOJHUtdqokoCnXw3it9xE6I7oUQM1mYz-woj7VUdX3M4tyOCTk-gcXYQnLB89Dz_XLXcYjpLrrk6NfLKxAF6yBhx51PGCnlAQx8GP2Kd44QCK-4HZx3Nss9QhojEgff8U0MKx_I0Rk77GEgPN_VU3Z7c327-D5Z_vz2YzFfTmxRajUB0LqVtdClhFaZrrKqtmhsZdrSVqq1BqAyWeq07vusVCWYblZXvZgJqItTdrldmw8_jkipWTuyOAzgMYzUKF3qUlRGVhm92KFju8au2US3hvjc7N-UAb0FbAxEEft3RIrmLY3m7zSaXRrZdvWPzbr058cpghv-Z55uzWHcfOzcbxYBrFM |
CitedBy_id | crossref_primary_10_1055_a_1550_3882 crossref_primary_10_1016_j_autrev_2022_103056 crossref_primary_10_7759_cureus_30145 crossref_primary_10_1016_j_resinv_2023_02_007 crossref_primary_10_1186_s40001_023_01384_0 crossref_primary_10_1186_s13075_021_02586_9 crossref_primary_10_2169_naika_112_1920 crossref_primary_10_1016_j_rcreue_2023_09_002 crossref_primary_10_1186_s12890_023_02532_2 crossref_primary_10_1097_CM9_0000000000002577 crossref_primary_10_1016_j_reumae_2022_03_004 crossref_primary_10_1055_s_0042_1755566 crossref_primary_10_1093_rheumatology_kead363 crossref_primary_10_1111_1756_185X_14351 crossref_primary_10_1016_j_rcreu_2023_09_006 crossref_primary_10_3389_fmed_2024_1465753 crossref_primary_10_1097_RTI_0000000000000734 crossref_primary_10_1186_s13075_024_03453_z crossref_primary_10_1002_JLB_3MA1221_489R crossref_primary_10_1186_s12931_022_01978_y crossref_primary_10_3390_diagnostics14171890 crossref_primary_10_1007_s00296_020_04773_4 crossref_primary_10_1513_AnnalsATS_202305_491OC crossref_primary_10_1183_23120541_00403_2024 crossref_primary_10_3390_diagnostics14131430 crossref_primary_10_47360_1995_4484_2022_1 crossref_primary_10_1093_mr_roac115 crossref_primary_10_1016_j_rmed_2022_106898 crossref_primary_10_1016_j_semarthrit_2022_152031 crossref_primary_10_1093_rheumatology_keac651 crossref_primary_10_1093_rheumatology_kead027 crossref_primary_10_1080_17476348_2022_2089116 crossref_primary_10_1002_acr2_11736 crossref_primary_10_3389_fphar_2022_941013 crossref_primary_10_1016_j_chstcc_2023_100020 crossref_primary_10_1177_1759720X221074457 crossref_primary_10_1186_s13075_021_02578_9 crossref_primary_10_7759_cureus_48016 crossref_primary_10_1016_j_rmcr_2023_101857 crossref_primary_10_1007_s10067_023_06623_7 crossref_primary_10_1016_j_ebiom_2024_105339 crossref_primary_10_1016_j_autrev_2023_103501 crossref_primary_10_1016_j_reuma_2022_03_005 crossref_primary_10_1016_j_autrev_2025_103804 crossref_primary_10_1298_ptr_E10188 crossref_primary_10_1038_s41584_021_00721_z crossref_primary_10_3389_fmed_2023_1129939 crossref_primary_10_7759_cureus_41155 crossref_primary_10_1186_s12864_023_09548_2 crossref_primary_10_58877_japaj_v2i1_125 crossref_primary_10_1002_jmv_29781 |
Cites_doi | 10.3899/jrheum.101261 10.1016/j.rmed.2008.12.019 10.1016/j.rmed.2012.07.006 10.3904/kjim.2016.349 10.1093/rheumatology/keq035 10.1378/chest.07-0323 10.1080/03009740601153774 10.1002/art.1780310302 10.1136/bmjopen-2018-028466 10.1007/s00296-010-1665-1 10.1093/rheumatology/keg466 10.1016/j.reuma.2011.12.008 10.1183/16000617.0050-2017 10.1001/archinternmed.2007.59 10.1164/rccm.2009-040GL 10.1002/art.38733 10.1164/rccm.200703-463PP 10.1093/rheumatology/kez337 10.1093/rheumatology/41.3.262 10.1007/s10067-015-3025-8 10.1038/s41584-019-0275-x 10.1002/art.27584 10.1093/rheumatology/kez177 10.1056/NEJMoa1801562 10.1136/bmjopen-2013-003132 10.3109/14397595.2016.1173816 10.1378/chest.09-0444 10.1002/art.1780401016 10.1002/art.27405 10.1378/chest.103.6.1808 |
ContentType | Journal Article |
Copyright | The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2020 The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com. |
Copyright_xml | – notice: The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2020 – notice: The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com. |
DBID | AAYXX CITATION NPM 7X8 |
DOI | 10.1093/rheumatology/keaa608 |
DatabaseName | CrossRef PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1462-0332 |
EndPage | 2354 |
ExternalDocumentID | 33241299 10_1093_rheumatology_keaa608 10.1093/rheumatology/keaa608 |
Genre | Journal Article |
GroupedDBID | --- -E4 .2P .GJ .I3 .XZ .ZR 08P 0R~ 18M 1TH 29P 2WC 354 3O- 4.4 48X 53G 5RE 5VS 5WA 5WD 70D AABZA AACZT AAGKA AAJKP AAJQQ AAMDB AAMVS AAOGV AAPGJ AAPNW AAPQZ AAPXW AARHZ AASNB AAUAY AAUQX AAVAP AAWDT AAWTL ABEUO ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPTD ABQLI ABQNK ABQTQ ABXVV ABZBJ ACFRR ACGFO ACGFS ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFNX AFFZL AFIYH AFOFC AFXAL AFXEN AGINJ AGKEF AGSYK AGUTN AHMBA AHXPO AIAGR AIJHB AJEEA AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN AQDSO ATGXG ATTQO AXUDD AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CAG CDBKE COF CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBD EBS EE~ EIHJH EJD EMOBN ENERS F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HVGLF HW0 HZ~ IOX J21 KAQDR KBUDW KC5 KOP KQ8 KSI KSN L7B M-Z M49 MHKGH N9A NGC NOMLY NOYVH NTWIH NU- NVLIB O0~ O9- OAUYM OAWHX OBH OCZFY ODMLO OHH OJQWA OJZSN OK1 OPAEJ OVD OWPYF O~Y P2P PAFKI PB- PEELM PQQKQ Q1. Q5Y R44 RD5 RHF RIG RNI ROL ROX RUSNO RW1 RXO RZF RZO SV3 TCURE TEORI TJX TMA TR2 VVN W8F WOQ X7H YAYTL YKOAZ YXANX ZGI ZKX ZY1 ~91 AAYXX ABDFA ABEJV ABGNP ABVGC ADNBA AEMQT AGORE AHGBF AHMMS AJBYB AJNCP ALXQX CITATION JXSIZ NPM 7X8 |
ID | FETCH-LOGICAL-c3642-aa44b190461ab28d7c29ce8c78b6c72bc8aa789ced44ffc7276a8d597f050a93 |
ISSN | 1462-0324 1462-0332 |
IngestDate | Fri Jul 11 04:49:12 EDT 2025 Thu Apr 03 07:09:37 EDT 2025 Tue Jul 01 04:04:20 EDT 2025 Thu Apr 24 23:10:58 EDT 2025 Wed Aug 28 03:18:56 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | MTX acute exacerbation usual interstitial pneumonia interstitial lung disease RA |
Language | English |
License | This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3642-aa44b190461ab28d7c29ce8c78b6c72bc8aa789ced44ffc7276a8d597f050a93 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-9724-4911 0000-0002-0022-1941 |
PMID | 33241299 |
PQID | 2464607817 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_2464607817 pubmed_primary_33241299 crossref_primary_10_1093_rheumatology_keaa608 crossref_citationtrail_10_1093_rheumatology_keaa608 oup_primary_10_1093_rheumatology_keaa608 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-May-14 |
PublicationDateYYYYMMDD | 2021-05-14 |
PublicationDate_xml | – month: 05 year: 2021 text: 2021-May-14 day: 14 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Rheumatology (Oxford, England) |
PublicationTitleAlternate | Rheumatology (Oxford) |
PublicationYear | 2021 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
References | Zamora-Legoff (2021051419010939900_keaa608-B28) 2017; 56 Kondoh (2021051419010939900_keaa608-B33) 2017; 26 Hozumi (2021051419010939900_keaa608-B6) 2013; 3 Aletaha (2021051419010939900_keaa608-B10) 2010; 62 Kondoh (2021051419010939900_keaa608-B3) 1993; 103 Restrepo (2021051419010939900_keaa608-B21) 2015; 34 Arnett (2021051419010939900_keaa608-B9) 1988; 31 Kiely (2021051419010939900_keaa608-B22) 2019; 9 Fragoulis (2021051419010939900_keaa608-B24) 2019; 58 Wolfe (2021051419010939900_keaa608-B17) 2007; 36 Juge (2021051419010939900_keaa608-B32) 2018; 379 Ota (2021051419010939900_keaa608-B7) 2017; 27 Suda (2021051419010939900_keaa608-B4) 2009; 103 Gochuico (2021051419010939900_keaa608-B15) 2008; 168 Kim (2021051419010939900_keaa608-B26) 2009; 136 Rojas-Serrano (2021051419010939900_keaa608-B23) 2014; 66 Koduri (2021051419010939900_keaa608-B19) 2010; 49 Duarte (2021051419010939900_keaa608-B25) 2019; 58 Saravanan (2021051419010939900_keaa608-B11) 2003; 43 Zou (2021051419010939900_keaa608-B20) 2012; 32 Dawson (2021051419010939900_keaa608-B18) 2002; 41 Yang (2021051419010939900_keaa608-B27) 2019; 34 Mori (2021051419010939900_keaa608-B30) 2012; 106 Park (2021051419010939900_keaa608-B5) 2007; 132 Bongartz (2021051419010939900_keaa608-B1) 2010; 62 Collard (2021051419010939900_keaa608-B2) 2007; 176 Rojas-Serrano (2021051419010939900_keaa608-B8) 2012; 8 Gaffo (2021051419010939900_keaa608-B16) 2008; 168 Aubart (2021051419010939900_keaa608-B29) 2011; 38 Song (2021051419010939900_keaa608-B14) 2013; 30 Wang (2021051419010939900_keaa608-B31) 2019; 15 Raghu (2021051419010939900_keaa608-B13) 2011; 183 Kremer (2021051419010939900_keaa608-B12) 1997; 40 |
References_xml | – volume: 38 start-page: 979 year: 2011 ident: 2021051419010939900_keaa608-B29 article-title: High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis publication-title: J Rheumatol doi: 10.3899/jrheum.101261 – volume: 168 start-page: 1927 year: 2008 ident: 2021051419010939900_keaa608-B16 article-title: Methotrexate is not associated with progression of interstitial lung disease in rheumatoid arthritis publication-title: Arch Intern Med – volume: 103 start-page: 846 year: 2009 ident: 2021051419010939900_keaa608-B4 article-title: Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases publication-title: Respir Med doi: 10.1016/j.rmed.2008.12.019 – volume: 106 start-page: 1591 year: 2012 ident: 2021051419010939900_keaa608-B30 article-title: Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis publication-title: Respir Med doi: 10.1016/j.rmed.2012.07.006 – volume: 34 start-page: 434 year: 2019 ident: 2021051419010939900_keaa608-B27 article-title: Clinical characteristics associated with occurrence and poor prognosis of interstitial lung disease in rheumatoid arthritis publication-title: Korean J Intern Med doi: 10.3904/kjim.2016.349 – volume: 49 start-page: 1483 year: 2010 ident: 2021051419010939900_keaa608-B19 article-title: Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/keq035 – volume: 132 start-page: 214 year: 2007 ident: 2021051419010939900_keaa608-B5 article-title: Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis publication-title: Chest doi: 10.1378/chest.07-0323 – volume: 36 start-page: 172 year: 2007 ident: 2021051419010939900_keaa608-B17 article-title: Rheumatoid arthritis treatment and the risk of severe interstitial lung disease publication-title: Scand J Rheumatol doi: 10.1080/03009740601153774 – volume: 31 start-page: 315 year: 1988 ident: 2021051419010939900_keaa608-B9 article-title: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis publication-title: Arthritis Rheum doi: 10.1002/art.1780310302 – volume: 9 start-page: e028466 year: 2019 ident: 2021051419010939900_keaa608-B22 article-title: Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts publication-title: BMJ Open doi: 10.1136/bmjopen-2018-028466 – volume: 32 start-page: 669 year: 2012 ident: 2021051419010939900_keaa608-B20 article-title: The clinical significance of HRCT in evaluation of patients with rheumatoid arthritis-associated interstitial lung disease: a report from China publication-title: Rheumatol Int doi: 10.1007/s00296-010-1665-1 – volume: 56 start-page: 344 year: 2017 ident: 2021051419010939900_keaa608-B28 article-title: Patterns of interstitial lung disease and mortality in rheumatoid arthritis publication-title: Rheumatology (Oxford) – volume: 43 start-page: 143 year: 2003 ident: 2021051419010939900_keaa608-B11 article-title: Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/keg466 – volume: 8 start-page: 68 year: 2012 ident: 2021051419010939900_keaa608-B8 article-title: Interstitial lung disease related to rheumatoid arthritis: evolution after treatment publication-title: Reumatol Clin doi: 10.1016/j.reuma.2011.12.008 – volume: 26 start-page: 170050 year: 2017 ident: 2021051419010939900_keaa608-B33 article-title: Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis publication-title: Eur Respir Rev doi: 10.1183/16000617.0050-2017 – volume: 168 start-page: 159 year: 2008 ident: 2021051419010939900_keaa608-B15 article-title: Progressive preclinical interstitial lung disease in rheumatoid arthritis publication-title: Arch Intern Med doi: 10.1001/archinternmed.2007.59 – volume: 183 start-page: 788 year: 2011 ident: 2021051419010939900_keaa608-B13 article-title: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.2009-040GL – volume: 66 start-page: 2641 year: 2014 ident: 2021051419010939900_keaa608-B23 article-title: Methotrexate and lung disease in rheumatoid arthritis: comment on the article by Conway et al publication-title: Arthritis Rheumatol doi: 10.1002/art.38733 – volume: 176 start-page: 636 year: 2007 ident: 2021051419010939900_keaa608-B2 article-title: Acute exacerbations of idiopathic pulmonary fibrosis publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200703-463PP – volume: 58 start-page: 1900 year: 2019 ident: 2021051419010939900_keaa608-B24 article-title: Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/kez337 – volume: 41 start-page: 262 year: 2002 ident: 2021051419010939900_keaa608-B18 article-title: Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests [published correction appears in Rheumatology (Oxford) 2002 May; 41(5):597] publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/41.3.262 – volume: 34 start-page: 1529 year: 2015 ident: 2021051419010939900_keaa608-B21 article-title: Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis publication-title: Clin Rheumatol doi: 10.1007/s10067-015-3025-8 – volume: 15 start-page: 581 year: 2019 ident: 2021051419010939900_keaa608-B31 article-title: Mechanisms of lung disease development in rheumatoid arthritis publication-title: Nat Rev Rheumatol doi: 10.1038/s41584-019-0275-x – volume: 62 start-page: 2569 year: 2010 ident: 2021051419010939900_keaa608-B10 article-title: 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative publication-title: Arthritis Rheum doi: 10.1002/art.27584 – volume: 58 start-page: 2031 year: 2019 ident: 2021051419010939900_keaa608-B25 article-title: The lung in a cohort of rheumatoid arthritis patients—an overview of different types of involvement and treatment publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/kez177 – volume: 379 start-page: 2209 year: 2018 ident: 2021051419010939900_keaa608-B32 article-title: MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease publication-title: N Engl J Med doi: 10.1056/NEJMoa1801562 – volume: 30 start-page: 103 year: 2013 ident: 2021051419010939900_keaa608-B14 article-title: Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia publication-title: Sarcoidosis Vasc Diffuse Lung Dis – volume: 3 start-page: e003132 year: 2013 ident: 2021051419010939900_keaa608-B6 article-title: Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study publication-title: BMJ Open doi: 10.1136/bmjopen-2013-003132 – volume: 27 start-page: 22 year: 2017 ident: 2021051419010939900_keaa608-B7 article-title: Efficacy of intensive immunosuppression in exacerbated rheumatoid arthritis-associated interstitial lung disease publication-title: Mod Rheumatol doi: 10.3109/14397595.2016.1173816 – volume: 136 start-page: 1397 year: 2009 ident: 2021051419010939900_keaa608-B26 article-title: Rheumatoid arthritis–associated interstitial lung disease: the relevance of histopathologic and radiographic pattern publication-title: Chest doi: 10.1378/chest.09-0444 – volume: 40 start-page: 1829 year: 1997 ident: 2021051419010939900_keaa608-B12 article-title: Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review publication-title: Arthritis Rheum doi: 10.1002/art.1780401016 – volume: 62 start-page: 1583 year: 2010 ident: 2021051419010939900_keaa608-B1 article-title: Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study publication-title: Arthritis Rheum doi: 10.1002/art.27405 – volume: 103 start-page: 1808 year: 1993 ident: 2021051419010939900_keaa608-B3 article-title: Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases publication-title: Chest doi: 10.1378/chest.103.6.1808 |
SSID | ssj0005138 |
Score | 2.3609214 |
Snippet | Abstract
Objectives
RA-associated interstitial lung disease (RA-ILD) is commonly associated with acute exacerbations (ILD-AE). This study examined the clinical... RA-associated interstitial lung disease (RA-ILD) is commonly associated with acute exacerbations (ILD-AE). This study examined the clinical characteristics and... |
SourceID | proquest pubmed crossref oup |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 2348 |
Title | Acute exacerbation of rheumatoid arthritis–associated interstitial lung disease: clinical features and prognosis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/33241299 https://www.proquest.com/docview/2464607817 |
Volume | 60 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NjtMwELbKIiEuiP_tLiAjcUBC2U0c54_bih-1oOUARVpOkeM4asiSoLSRlj3xDjwZr8CTMI4dx9WCtnBo1LiJo3q-jMfjmW8QehLkGY8zEjuy_JsjVwhOlnjE4TQqApJ7OQlk7vDxu3D2kb45CU4mk59W1FK3zg74-R_zSv5HqtAGcpVZsv8gWdMpNMB3kC8cQcJw3ErGR1zu8oszxmFwjO3XLkUHdmhT5pLBaNmzFg0xDT7T4hB5zxTRylAB6TQ_hZd-2K2RXgKTMVmInvpzpRkFGhmYV65sm_a9fl5P5iTZS8-GgHldIcTyNszPu6o3Vz8sy_pzaXQO-yKLOilLdla2zbeuMj_OM-X7lXTAo6OhkrlofUXiZ5-6qrG9F8STG-_e6L38S1akpZBpSBzXV3nWB8Ju8ze0uKpKoNEa2CrZV1SeenonviKtvjB1KFqt1hoyOK0EY6Ebj5OlCWG87JYr6CqBlYssqvFy_naMOvL64urmbw3ZnIl_aPdzqHvZsJY2MjAvLIR6g2hxE93QKxl8pGB5C01EfRtdO9axGndQ26MT2-jETYFHdGKDzl_ff4y4xDYuscQl1rh8jgdU4gGVGOCFDSrvosXrV4sXM0dX-HC4DwtfhzFKMzBJaegxUBh5xEnCRcyjOAt5RECNMBbF0JRTWhTQEoUszmENXLiByxL_Htqpm1rsIpwERQyGFaeEw4cIRlzB4KrcCzIiAneK_GEgU67Z72URltNURWH4qT38qR7-KXLMXV8V-8sl1z8FGW156eNBkClodLlNx2rRdKuU0JCGkoMrmqL7SsKmRwA9BQs92dv-Qfvo-vjiPUA767YTD8GQXmePemj-Bk-g1w0 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Acute+exacerbation+of+rheumatoid+arthritis%E2%80%93associated+interstitial+lung+disease%3A+clinical+features+and+prognosis&rft.jtitle=Rheumatology+%28Oxford%2C+England%29&rft.au=Izuka%2C+Shinji&rft.au=Yamashita%2C+Hiroyuki&rft.au=Iba%2C+Arisa&rft.au=Takahashi%2C+Yuko&rft.date=2021-05-14&rft.pub=Oxford+University+Press&rft.issn=1462-0324&rft.eissn=1462-0332&rft.volume=60&rft.issue=5&rft.spage=2348&rft.epage=2354&rft_id=info:doi/10.1093%2Frheumatology%2Fkeaa608&rft.externalDocID=10.1093%2Frheumatology%2Fkeaa608 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-0324&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-0324&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-0324&client=summon |